| Title |
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US
|
|---|---|
| Published in |
CNS Drugs, November 2018
|
| DOI | 10.1007/s40263-018-0589-2 |
| Pubmed ID | |
| Authors |
Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton, Maria Roberta Cilio |
X Demographics
The data shown below were collected from the profiles of 72 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 12 | 17% |
| United Kingdom | 6 | 8% |
| Canada | 5 | 7% |
| Japan | 4 | 6% |
| Denmark | 2 | 3% |
| Netherlands | 2 | 3% |
| Australia | 2 | 3% |
| Sweden | 2 | 3% |
| Norway | 1 | 1% |
| Other | 2 | 3% |
| Unknown | 34 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 56 | 78% |
| Scientists | 12 | 17% |
| Practitioners (doctors, other healthcare professionals) | 4 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 153 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 153 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 10% |
| Student > Bachelor | 16 | 10% |
| Researcher | 15 | 10% |
| Student > Ph. D. Student | 15 | 10% |
| Other | 10 | 7% |
| Other | 23 | 15% |
| Unknown | 58 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 23% |
| Neuroscience | 11 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Psychology | 8 | 5% |
| Nursing and Health Professions | 7 | 5% |
| Other | 21 | 14% |
| Unknown | 62 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 48. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2022.
All research outputs
#887,453
of 25,784,004 outputs
Outputs from CNS Drugs
#68
of 1,403 outputs
Outputs of similar age
#19,598
of 449,305 outputs
Outputs of similar age from CNS Drugs
#2
of 16 outputs
Altmetric has tracked 25,784,004 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,403 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,305 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.